Onko-Gene

Critical literature watch in the molecular oncology of solid tumors

FREN

Clinical · Molecular biology · Bioinfo & AI

Transcriptome-based epigenetic screening identifies DNA hypermethylation signatures as prognostic biomarkers in oral squamous cell carcinoma

Summary

This study identified and validated novel promoter DNA hypermethylation signatures as prognostic biomarkers in oral squamous cell carcinoma (OSCC). Combining a discovery approach based on pharmacologic demethylation and RNA sequencing with multi-platform validation, five candidate genes (GPX3, ANG, CTGF, GPRC5B, BAMBI) were identified. Their promoter hypermethylation is associated with cancer-specific transcriptional and protein silencing. Notably, CTGF hypermethylation was independently associated with poor overall survival, and a combined ANG+CTGF signature demonstrated superior and reproducible prognostic performance. These findings pave the way for clinical risk stratification in OSCC patients.

Critical appraisal

Clinical. This study identifies CTGF hypermethylation, alone or in combination with ANG, as a robust prognostic biomarker for oral squamous cell carcinoma (OSCC), associated with poor overall survival (p=0.03 in the institutional cohort, p=0.01 in TCGA-HNSC). This is a prognostic biomarker, enabling the identification of high-risk patients. These findings could justify clinical trials aimed at evaluating the impact of risk stratification based on this biomarker on therapeutic decisions. The time to clinical impact could be 3-5 years, following prospective validation in larger cohorts and the establishment of clinical thresholds.

Molecular biology. The discovery of these epigenetic biomarkers was achieved through an innovative approach combining pharmacologic demethylation and RNA sequencing on OSCC cell lines. Validation was rigorous, employing techniques such as quantitative RT-PCR, methylation-specific PCR, bisulfite sequencing, and immunohistochemistry, confirming transcriptional and protein silencing. Samples used included cell lines, normal oral mucosa, and primary OSCC tumors, as well as TCGA-HNSC data, ensuring good representativeness. The nature of the alteration (DNA hypermethylation) is a key gene silencing mechanism, and its detection could be integrated into molecular diagnostic panels.

Bioinfo & AI. The study utilized bioinformatic data from TCGA-HNSC for independent confirmation of hypermethylated genes and their inverse correlation with expression, strengthening the validity of the discoveries. Pathway analysis linked the identified genes to epithelial-mesenchymal transition and interferon response signaling, providing biological context. The integration of these clinical and molecular data with bioinformatic tools is crucial for biomarker identification and validation, and could eventually be deployed clinically to prioritize patients for multidisciplinary team discussions or specific clinical trials.

The summary and the appraisal were written by a language model from the title and abstract of the original article. A curator decided to publish it. Methodology